Faisal Khurshid

Stock Analyst at Leerink Partners

(0.73)
# 2500
Out of 5,438 analysts
24
Total ratings
Success rate
Average return
19 Stocks
Name Action PT Current % Upside Ratings Updated
STTK Shattuck Labs
Maintains: Outperform
4 2
0.74 170.27% 2 Aug 14, 2025
RYTM Rhythm Pharmaceutica...
Maintains: Outperform
88 102
94.32 8.14% 2 Jul 10, 2025
ABCL AbCellera Biologics
Assumes: Outperform
5
4.5 11.11% 1 Jul 7, 2025
IRWD Ironwood Pharmaceuti...
Maintains: Market Perform
3 1
0.84 19.05% 2 Apr 14, 2025
SYRE Spyre Therapeutics
Initiates Coverage On: Outperform
45
15.22 195.66% 1 Apr 8, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Market Perform
16
9.64 65.98% 1 Mar 17, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
33 2
1.69 18.34% 2 Mar 3, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
16
5.61 185.2% 1 Feb 18, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
60 60
37.69 59.19% 2 Dec 27, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
80
84.89 -5.76% 1 Dec 11, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
15
1.41 963.83% 1 Nov 4, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Outperform
7
7.33 -4.5% 1 Sep 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Outperform
45
17.1 163.16% 1 Sep 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Market Perform
24
31.5 -23.81% 1 Sep 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
7
1.35 418.52% 1 Sep 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Outperform
8
3.42 133.92% 1 Sep 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Outperform
5
0.84 495.24% 1 Sep 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
17 21
21.55 -2.55% 1 Mar 19, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
11
3.64 202.2% 1 Mar 21, 2023